INCB 62079

Drug Profile

INCB 62079

Alternative Names: INCB62079

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Liver cancer

Most Recent Events

  • 22 Mar 2017 Pharmacodynamics data from a preclinical study in Liver cancer released by Incyte corporation (Incyte corporation form 10-k, March 2017)
  • 14 Feb 2017 Incyte Corporation plans a phase I/II trial for Hepatocellular carcinoma
  • 12 Jan 2017 Preclinical trials in Liver cancer in USA before January 2017 (Incyte Corporation pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top